|
Correlation between clinicopathological factors and molecular markers |
||||||
| HER2 |
P53 |
Ki67 |
||||
|
|
||||||
| Positive/total (percentage) |
P |
Positive/total (percentage) |
P |
Positive/total (percentage) |
P |
|
|
|
||||||
| Total |
9/73 (12.3) |
16/73 (21.9) |
26/73 (35.6) |
|||
| Tumour size (cm) |
||||||
| <2.0 |
4/20 (20.0) |
0.41 |
5/20 (25.0) |
0.94 |
7/20 (35.0) |
>0.99 |
| ≥2.0 |
5/53 (9.4) |
11/53 (20.8) |
19/53 (35.8) |
|||
| Number of positive lymph nodes |
||||||
| 0 |
1/22 (4.5) |
0.34 |
3/22 (12.6) |
0.41 |
6/22 (27.2) |
0.47 |
| ≥1 |
8/51 (15.7) |
13/51 (25.5) |
20/51 (39.2) |
|||
| Histological grade |
||||||
| 1 |
0/12 (0) |
0.36 |
0/12 (0) |
0.05 |
3/12 (25.0) |
0.18 |
| 2 |
6/42 (14.3) |
9/42 (21.4) |
13/42 (31.0) |
|||
| 3 |
3/19 (15.8) |
7/19 (36.8) |
10/19 (52.6) |
|||
| Estrogen receptor-α |
||||||
| Negative |
4/17 (23.5) |
0.23 |
5/17 (29.4) |
0.60 |
8/17 (47.1) |
0.40 |
| Positive |
5/56 (8.9) |
11/56 (19.6) |
18/56 (32.1) |
|||
| Progesterone receptor |
||||||
| Negative |
3/18 (16.7) |
0.81 |
5/18 (27.8) |
0.71 |
9/18 (50.0) |
0.23 |
| Positive |
6/55 (10.9) |
11/55 (20.0) |
17/55 (30.9) |
|||
Yamashita et al. Breast Cancer Research 2006 8:R48 doi:10.1186/bcr1536 |
||||||